Celldex Therapeutics (CLDX) Posts Narrower than Expected Q2 Loss of 27c/Sh.

Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.95 million versus the consensus estimate of $2.43 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Celldex Therapeutics (CLDX) PT Raised to $53 at Barclays
• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• RideNow Group, Inc. (RDNW) Tops Q2 EPS by 4c